Market Snapshot: Zaltrap Changes Cost-Benefit Expectations For New Colon Cancer Drugs
Executive Summary
Lilly’s Cyramza, Boehringer Ingelheim’s Vargatef and Taiho’s TAS-102 will join an increasingly crowded and price sensitive market in metastatic colorectal cancer in the coming years.